Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029

Loading news article.

Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029 | WAPE

Sionna Therapeutics To Advance SION-451/SION-2222 CF Combo Into Phase 2a; Cuts Workforce By 46% To Extend Cash Runway Into The Second Half Of 2029

Article summary

Related companies

Analyzed by WAPE AI.

Comments —